Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.